Medtronic launches renal stent system in Europe:
This article was originally published in Clinica
Medtronic has launched its next-generation renal stent system, the Bridge X3, in Europe and other major markets outside the US. The device has a low crossing profile - it can be delivered through a 6 French sheath - it has high radial strength and has improved scaffolding due to having shorter element lengths, the company says. The product is not for sale in the US, where it is an investigational device.
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.